Thomas S Uldrick1, Sharon Pipkin, Susan Scheer, Nancy A Hessol. 1. aHIV & AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute at the National Institutes of Health, Bethesda, Maryland bSan Francisco Department of Public Health cDepartments of Clinical Pharmacy & Medicine, University of California, San Francisco, California, USA.
Abstract
OBJECTIVE: AIDS-related primary central nervous system lymphoma (AR-PCNSL) has a poor prognosis. Improved understanding of specific patient, infectious, diagnostic, and treatment-related factors that affect overall survival (OS) is required to improve outcomes. DESIGN: Population-based registry linkage study. METHODS: Adult cases from the San Francisco AIDS registry (1990-2000) were matched with the California Cancer Registry (1985-2002) to ascertain AR-PCNSL data. Survival time was assessed through 31 December 2007. Risk factors and temporal trends for death were measured using two-sided Kaplan-Meier and Cox analyses. RESULTS: Two hundred and seven AR-PCNSL patients were identified: 68% were white, 20% Hispanic, 10% African-American, and 2% Asian. Nineteen percent of patients had central nervous system (CNS) opportunistic infections diagnosed prior to AR-PCNSL. Fifty-seven percent of patients received radiation and/or chemotherapy and 12% used HAART prior to or within 30 days of AR-PCNSL diagnosis. One hundred and ninety-nine patients died (34 deaths/100 person-years). In adjusted analysis, prior CNS opportunistic infection diagnosis increased risk of death (hazard ratio 1.9, P = 0.0006) whereas radiation and/or chemotherapy decreased risk (hazard ratio 0.6, P < 0.0001). AR-PCNSL diagnosis 1999-2002 had a lower mortality risk (hazard ratio = 0.4, P = 0.02) compared to 1990-1995. African-Americans had an increased risk of death compared to whites or Asians (hazard ratio = 2.0, P = 0.007). CONCLUSION: OS among AR-PCNSL patients improved over time but remains poor, especially among African-Americans. Prospective evaluation of curative therapy in AR-PCNSL is urgently needed. Accurate diagnosis of CNS mass lesions in patients with AIDS is required and for those with AR-PCNSL, antiretroviral therapy with concomitant AR-PCNSL therapy, and antimicrobial supportive care may improve OS.
OBJECTIVE:AIDS-related primary central nervous system lymphoma (AR-PCNSL) has a poor prognosis. Improved understanding of specific patient, infectious, diagnostic, and treatment-related factors that affect overall survival (OS) is required to improve outcomes. DESIGN: Population-based registry linkage study. METHODS: Adult cases from the San Francisco AIDS registry (1990-2000) were matched with the California Cancer Registry (1985-2002) to ascertain AR-PCNSL data. Survival time was assessed through 31 December 2007. Risk factors and temporal trends for death were measured using two-sided Kaplan-Meier and Cox analyses. RESULTS: Two hundred and seven AR-PCNSLpatients were identified: 68% were white, 20% Hispanic, 10% African-American, and 2% Asian. Nineteen percent of patients had central nervous system (CNS) opportunistic infections diagnosed prior to AR-PCNSL. Fifty-seven percent of patients received radiation and/or chemotherapy and 12% used HAART prior to or within 30 days of AR-PCNSL diagnosis. One hundred and ninety-nine patients died (34 deaths/100 person-years). In adjusted analysis, prior CNS opportunistic infection diagnosis increased risk of death (hazard ratio 1.9, P = 0.0006) whereas radiation and/or chemotherapy decreased risk (hazard ratio 0.6, P < 0.0001). AR-PCNSL diagnosis 1999-2002 had a lower mortality risk (hazard ratio = 0.4, P = 0.02) compared to 1990-1995. African-Americans had an increased risk of death compared to whites or Asians (hazard ratio = 2.0, P = 0.007). CONCLUSION:OS among AR-PCNSLpatients improved over time but remains poor, especially among African-Americans. Prospective evaluation of curative therapy in AR-PCNSL is urgently needed. Accurate diagnosis of CNS mass lesions in patients with AIDS is required and for those with AR-PCNSL, antiretroviral therapy with concomitant AR-PCNSL therapy, and antimicrobial supportive care may improve OS.
Authors: Roland Schroers; Alexander Baraniskin; Christoph Heute; Matthias Vorgerd; Anna Brunn; Jan Kuhnhenn; Annika Kowoll; Andriy Alekseyev; Wolff Schmiegel; Uwe Schlegel; Martina Deckert; Hendrik Pels Journal: Eur J Haematol Date: 2010-10-28 Impact factor: 2.997
Authors: Jaco Kraan; Jan W Gratama; Corinne Haioun; Alberto Orfao; Anne Plonquet; Anna Porwit; Sandra Quijano; Maryalice Stetler-Stevenson; Dolores Subira; Wyndham Wilson Journal: Curr Protoc Cytom Date: 2008-07
Authors: Gregorio A Millett; John L Peterson; Stephen A Flores; Trevor A Hart; William L Jeffries; Patrick A Wilson; Sean B Rourke; Charles M Heilig; Jonathan Elford; Kevin A Fenton; Robert S Remis Journal: Lancet Date: 2012-07-20 Impact factor: 79.321
Authors: A Cingolani; A De Luca; L M Larocca; A Ammassari; M Scerrati; A Antinori; L Ortona Journal: J Natl Cancer Inst Date: 1998-03-04 Impact factor: 13.506
Authors: Eric A Engels; Ruth M Pfeiffer; James J Goedert; Phillip Virgo; Timothy S McNeel; Steven M Scoppa; Robert J Biggar Journal: AIDS Date: 2006-08-01 Impact factor: 4.177
Authors: J J Goedert; T R Coté; P Virgo; S M Scoppa; D W Kingma; M H Gail; E S Jaffe; R J Biggar Journal: Lancet Date: 1998-06-20 Impact factor: 79.321
Authors: J E C Bromberg; D A Breems; J Kraan; G Bikker; B van der Holt; P Sillevis Smitt; M J van den Bent; M van't Veer; J W Gratama Journal: Neurology Date: 2007-05-15 Impact factor: 9.910
Authors: Kathryn Lurain; Thomas S Uldrick; Ramya Ramaswami; Mark N Polizzotto; Priscila H Goncalves; Anaida Widell; Seth M Steinberg; Elaine S Jaffe; Stefania Pittaluga; Hao-Wei Wang; Constance M Yuan; Mary Anne Tamula; Staci Martin; Pamela L Wolters; Jomy George; Richard F Little; Robert Yarchoan Journal: Blood Date: 2020-11-05 Impact factor: 22.113
Authors: Sarah M Kranick; Priscila H Goncalves; Maryalice Stetler-Stevenson; Karen Aleman; Mark N Polizzotto; Richard F Little; Robert Yarchoan; Thomas S Uldrick Journal: Haematologica Date: 2014-10-10 Impact factor: 9.941
Authors: Neel K Gupta; Amber Nolan; Antonio Omuro; Erin G Reid; Chia-Ching Wang; Gabriel Mannis; Michael Jaglal; Julio C Chavez; Paul G Rubinstein; Ann Griffin; Donald I Abrams; Jimmy Hwang; Lawrence D Kaplan; Judith A Luce; Paul Volberding; Patrick A Treseler; James L Rubenstein Journal: Neuro Oncol Date: 2016-08-30 Impact factor: 12.300
Authors: Lilie L Lin; David S Lakomy; Elizabeth Y Chiao; Robert M Strother; Meg Wirth; Ethel Cesarman; Margaret Borok; Naftali Busakhala; Carla J Chibwesha; Lameck Chinula; Ntokozo Ndlovu; Jackson Orem; Warren Phipps; Vikash Sewram; Samantha L Vogt; Joseph A Sparano; Ronald T Mitsuyasu; Susan E Krown; Satish Gopal Journal: JCO Glob Oncol Date: 2020-07